Biblio Discovery — Demo Discovery Service

10 results for "Ferras Alashkar"

Showing 1–10 · 1.17 seconds · RSS

  1. Journal Article

    Successful Treatment of Aplastic Anemia With Eltrombopag During Pregnancy: A Short Report

    Sandra M. Frey; Ferras Alashkar; H. Christian Reinhardt et al.

    eJHaem, Vol. 7 No. 2 · 2026 · English · DOAJ

    ABSTRACT Introduction Aplastic anemia (AA) is a rare bone marrow failure syndrome with pancytopenia, mainly due to immune‐mediated stem cell destruction. First‐line therapy for acquired severe AA ≥ 50 years/non‐severe AA (NSAA) requiring treatment is immunosuppressive therapy with horse…

  2. Journal Article Full text

    No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab

    Ferras Alashkar; Scott Rottinghaus; Colin Vance et al.

    PLOS ONE, Vol. 15 No. 3 · 2020 · English · PLOS Scopus

    Introduction: Ravulizumab (ALXN1210) is a long-lasting recycling IgG monoclonal antibody with an increased affinity for the neonatal Fc receptor (FcRn). The FcRn is essential for regulating IgG homeostasis. Saturation of the FcRn pathway is seen under high IgG doses as they compete with endogenous…

    Also available at: DOAJ

  3. Journal Article

    Cytopenia first – hepatitis second: an unusual sequence in aplastic anemia

    Ferras Alashkar; Daniel Föhring; Ulrich Dührsen et al.

    Clinical Case Reports, Vol. 5 No. 6 · 2017 · English · DOAJ Dropped by Scopus 2021

    Key Clinical Message To the best of our knowledge, this is the first report of aplastic anemia (AA) preceding autoantibody‐negative autoimmune hepatitis (AIH) with successful treatment of both conditions with the same immunosuppressive regimen, resulting in hematopoietic reconstitution and…

  4. Journal Article

    Crizanlizumab in adult patients with sickle cell disease: a retrospective German analysis

    Friederike Poppenborg; Alexander Röth; Raina Yamamoto et al.

    Frontiers in Hematology, Vol. 3 · 2024 · English · DOAJ Scopus

    IntroductionThe marketing authorization for crizanlizumab (Adakveo®), indicated for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell patients (pts) aged ≥16, was revoked by the European Medicines Agency (EMA) as the STAND study did not demonstrate a significant difference…

  5. Journal Article

    Safety and efficacy of voxelotor in adult patients with sickle cell disease

    Friederike Poppenborg; Raina Yamamoto; Sandra Maria Frey et al.

    Blood Red Cells & Iron, Vol. 2 No. 3 · 2026 · English · DOAJ

    Abstract: On 25 September 2024, Pfizer announced the voluntary withdrawal of voxelotor because of an imbalance in vaso-occlusive crises (VOCs) and fatal events. Medical records of 31 patients with sickle cell disease (SCD) (October 2021-September 2024; median age, 33 years [range 21-55; homozygous…

  6. Journal Article

    Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia–Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation

    Ferras Alashkar; Fuat H. Saner; Colin Vance et al.

    Frontiers in Medicine, Vol. 7 · 2020 · English · DOAJ Scopus

    Pregnancies in paroxysmal nocturnal hemoglobinuria (PNH) are associated with increased morbidity and mortality. Retrospective studies suggest that outcome has improved with the advent of the complement inhibitor eculizumab. To substantiate this assumption we analyzed the data from patients treated…

  7. Journal Article

    Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study

    Maria Domenica Cappellini; Mrudula B. Glassberg; Juliana Meyers et al.

    Therapeutic Advances in Hematology, Vol. 15 · 2024 · English · DOAJ Scopus

    Background: Beta-thalassemias (BTs) are characterized by deficient or absent synthesis of the beta-globin subunit, leading to anemia. Patient characteristics and treatment patterns in these patients may vary. Objective: This retrospective study evaluated demographics, clinical characteristics, and…

  8. Journal Article

    Screening and diagnosis of hemoglobinopathies in Germany: Current state and future perspectives

    Carmen Aramayo-Singelmann; Susan Halimeh; Pia Proske et al.

    Scientific Reports, Vol. 12 No. 1 · 2022 · English · DOAJ Scopus

    Abstract This monocentric study conducted at the Pediatric and Adult Hemoglobinopathy Outpatient Units of the University Hospital of Essen summarizes the results of hemoglobinopathies diagnosed between August 2018 and September 2021, prior to the introduction of a general newborn screening (NBS)…